Drug-induced headache: an analysis of therapeutic strategies
Abstract
To manage patients with drug-induced headache (DIH) is an unsolved problem of modern neurology in developed countries, since DIH is becoming a common cause of temporary disability and leads to lower quality of life in patients. Patients with primary headache (for example, those with tension headache or migraine) frequently take symptomatic headache relief medications uncontrollably, which can result in the higher frequency and intensity of DIH episodes. In turn, new headache attacks make the patients take the increasing number of symptomatic medications, which leads to the development of DIH.
The International Classification of Headache Disorders, 3 rd Edition, defines DIH as a distinct form of secondary headache. To date, there is no consensus on the tactics of DIH treatment and prevention. The paper discusses different approaches to DIH prevention and treatment, the effectiveness and appropriateness of their use, as well as factors influencing illness course and possible outcomes. Particular attention is paid to the management of patients during the withdrawal period, risk factors for DIH recurrences, and ways of their prevention.
About the Authors
P. A. Merbaum
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery
11, Rossolimo St., Build. 1, Moscow 119021
G. R. Tabeeva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Guzyal Rafkatovna Tabeeva
Department of Nervous System Diseases and Neurosurgery
11, Rossolimo St., Build. 1, Moscow 119021
A. V. Sergeev
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery
11, Rossolimo St., Build. 1, Moscow 119021
References
1. Bendtsena L, Eversb S, Lindec M, et al. EFNS guideline on the treatment of tension-type headache – Report of an EFNS task force. Eur J Neurol. 2010 Nov;17(11):1318-25. doi: 10.1111/j.1468-1331.2010.03070.x
2. Estemalik E, Tepper S. Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat. 2013;9:709-20. doi: 10.2147/NDT.S33769
3. Akhmadeeva LR, Azimova YuE, Karakulova YuV, et al. Clinical recommendations for the diagnosis and treatment of tension headache. RMZh. 2016;(7):411-9 (In Russ.).
4. Rossiyskoe obshchestvo po izucheniyu golovnoy boli. Klinicheskie rekomendatsii po vedeniyu vzroslykh patsientov s migren'yu. Rossiyskoe obshchestvo po izucheniyu golovnoy boli (ROIGB), Vserossiyskoe obshchestvo nevrologov (VON), 2016 g. [Russian society for the study of headache. Clinical guidelines for the management of adult migraine patients. Russian Society for the Study of Headache, All-Russian Society of Neurologists, 2016]. Available at: https://medi.ru/klinicheskie-rekomendatsii/migren-u-vzroslykh_14074/ (In Russ.).
5. Da Silva AN, Lake AE. Clinical aspects of medication overuse headaches. Headache: J Head Face Pain. 2013;54(1):211-7. doi: 10.1111/head.12223
6. Colas R, Munoz P, Temprano R, et al. Chronic daily headache with analgesic overuse: Epidemiology and impact on quality of life. Neurology. 2004;62(8):1338-42. doi: 10.1212/01.WNL.0000120545.45443.93
7. Headache Classification Committee of the International Headache Society (2018) Headache classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3 rd edition. Cephalalgia. 2018;38:1-211. doi: 10.1177/0333102417738202
8. Saper J, Lake A. Medication overuse headache: type I and type II. Cephalalgia. 2006;26(10):1262. doi: 10.1111/j.14682982.2006.01198.x
9. Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2011 Mar;18(3):396-401. doi: 10.1111/j.14681331.2010.03157.x
10. Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006 Sep;26(9):1097-105. doi: 10.1111/j.14682982.2006.01175.x
11. Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012;13:281-90. doi: 10.1007/s10194-0120432-y
12. Bekkelund SI, Salvesen R. Patient satisfaction with a neurological specialist consultation for headache. Scand J Prim Health Care. 2002;20:157-60. doi: 10.1080/028134302760234609
13. Hedenrud T, Babic N, Jonsson P. Medication overuse headache: self-perceived and actual knowledge among pharmacy staff. Headache. 2014 Jun;54(6):1019-25. doi: 10.1111/head.12350
14. Carlsen LN, Westergaard ML, Bisgaard M, et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018 Jun;38(7):1316-25. doi: 10.1177/0333102417736898
15. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: The effect of a 2-month drug-free period. Neurology. 2006;66(12):1894-8. doi: 10.1212/01.wnl.0000217914.30994.bd
16. Nielsen M, Carlsen LN, Munksgaard SB, et al. Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial. Cephalalgia. 2019 Jun;39(7):863-72. doi: 10.1177/0333102419828994
17. Katsarava Z, Obermann M. Medicationoveruse headache. Curr Opin Neurol. 2013 Jun;26(3):276-81. doi: 10.1097/WCO.0b013e328360d596
18. Evers S, Jensen R; European Federation of Neurological Societies. Treatment of medication overuse headache – guideline of the EFNS headache panel. Eur J Neurol. 2011 Sep;18(9):1115-21. doi: 10.1111/j.14681331.2011.03497.x
19. Kristoffersen ES, Lundqvist C. Medicationoveruse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014 Apr;5(2):87-99. doi: 10.1177/2042098614522683
20. Bottiroli S, Allena M, Sances G, et al. COMOESTAS Consortium. Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A sixmonth follow-up of the COMOESTAS Project. Cephalalgia. 2018 Jan 1:333102418783317. doi: 10.1177/0333102418783317
21. Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014;34(9):645-55. doi: 10.1177/0333102414521508
22. Weatherall MW, Telzerow AJ, Cittadini E, et al. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology. 2010;75(12):1098-103. doi: 10.1212/WNL.0b013e3181f39a11
23. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995-7. doi: 10.1212/WNL.36.7.995
24. Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache J Head Face Pain. 1987;27:130-3. doi: 10.1111/j.1526-4610.1987.hed2703130.x
25. Probyn K, Bowers H, Caldwell F, et al. Prognostic factors for chronic headache. Neurology. 2017;89:291-301. doi: 10.1212/WNL.0000000000004112
26. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827-32. doi: 10.1212/WNL.0b013e3182377dbb
27. Cevoli S, Giannini G, Favoni V, et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain. 2017;18(1):56. doi: 10.1186/s10194-017-0763-9
28. Diener HC, Bussone G, van Oene JC, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-23. doi: 10.1111/j.1468-2982.2007.01326.x
29. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo controlled trial. Headache. 2007;47:170-80. doi: 10.1111/j.15264610.2006.00684.x
30. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358-73. doi: 10.1111/j.15264610.2011.01990.x
31. Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2015;36:371-86. doi: 10.1177/0333102415593088
32. Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate, 2018. J Headache Pain. 2018;19(1):50. doi: 10.1186/s10194-018-0875-x
33. Mark W. The diagnosis and treatment of chronic migraine. Weatherall Ther Adv Chronic Dis. 2015 May;6(3):115-23. doi: 10.1177/2040622315579627
34. Ghadiri-Sani M, Silver N. Headache (chronic tension-type). BMJ Clin. Evid. 2016;5:1205.
35. Russell MB, Lundqvist C. Prevention and management of medication overuse headache. Curr Opin Neurol. 2012 Jun;25(3):290-5. doi: 10.1097/WCO.0b013e328352c431
36. Silberstein SD, Blumenfeld AM, Cady RK, et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48-56. doi: 10.1016/j.jns.2013.05.003
37. Tepper SJ, Dinner H-C, Ashina M, et al. Erenumab in patients with chronic migraine with medication overuse. Neurology. 2019 May 14;92(20):2309-20. doi: 10.1212/WNL.0000000000007497
38. Hagen K, Jensen R, Boe MG, Stovner LJ. Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. 2010 Oct;11(5):373-7. doi: 10.1007/s10194-010-0221-4
39. Zidverc-Trajkovic JJ, Pekmezovic T, Jovanovic Z, et al. Long-term predictors of remission in patients treated for medicationoveruse headache at a specialized headache center: A prospective cohort study. Cephalalgia. 2016;0(0):1-9.
40. Boe MG, Thortveit E, Vatne A, Mygland A. Chronic headache with medication overuse: Long-term prognosis after withdrawal therapy. Cephalalgia. 2016;37(13):1215-21. doi: 10.1177/0333102416672493
41. Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12-5. doi: 10.1111/j.14682982.2004.00789.x
42. Schnider P, Aull S, Baumgartner C, et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up. Cephalalgia. 1996;16:481-5. doi: 10.1046/j.1468-2982.1996.1607481.x
43. Suhr B, Evers S, Bauer B, et al. Druginduced headache: long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia. 1999;19:44-9. doi: 10.1111/j.14682982.1999.1901044.x
44. Fritsche G, Eberl A, Katsarava Z, et al. Drug-induced headache: longterm follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol. 2001;45:229-35. doi: 10.1159/000052134
45. Pini L-A, Cicero A, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia. 2001;21:878-83. doi: 10.1046/j.14682982.2001.00288.x
46. Sances G, Ghiotto N, Galli F, et al. Risk factors in medication-overuse headache: a 1-year follow-up study (care II protocol). Cephalalgia. 2010;30:329-36. doi: 10.1111/j.1468-2982.2009.01934.x
47. Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al. Medication overuse headache: Clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007;27:1219-25. doi: 10.1111/j.1468-2982.2007.01432.x
48. Munksgaard S, Bendtsen L, Jensen R. Treatment resistant medication overuse headache can be cured. Headache. 2012;52:1120-9. doi: 10.1111/j.1526-4610.2012.02191.x
49. Rossi P, Jensen J, Nappi G, Allena M. The COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain. 2009;10:407-17. doi: 10.1007/s10194-009-0159-6
50. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006;26(10):1192-8. doi: 10.1111/j.1468-2982.2006.01190.x
51. Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006 Sep-Oct;29(5):269-75. doi: 10.1097/01.WNF.000022888.49044.99
52. De Goffau MJ, Klaver ARE, Willemsen MG, et al. The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis. J Pain. 2017;18(6):615-27. doi: 10.1016/j.jpain.2016.12.005
Review
For citations:
Merbaum P.A., Tabeeva G.R., Sergeev A.V. Drug-induced headache: an analysis of therapeutic strategies. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):25-31. (In Russ.) https://doi.org/10.14412/2074-2711-2020-4-25-31
Views: 758
Email this article 